Zain Ebrahim
Stock Analyst at J.P. Morgan
(1.96)
# 2,938
Out of 5,073 analysts
40
Total ratings
61.9%
Success rate
0.9%
Average return
Main Sectors:
Stocks Rated by Zain Ebrahim
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LON: GSK GSK plc | Reiterated: Sell | 1,700p | 1,871p | -9.14% | 31 | Oct 21, 2026 | |
| SWX: BANB Bachem Holding AG | Reiterated: Buy | CHF 85.00 → CHF 90.00 | CHF 84.15 | +6.95% | 4 | Sep 10, 2026 | |
| EPA: EAPI Euroapi S.A. | Reiterated: Hold | €1.70 | €0.76 | +124.27% | 1 | May 13, 2026 | |
| LON: HIK Hikma Pharmaceuticals PLC | Reiterated: Buy | 2,400p → 2,000p | 1,667p | +19.98% | 2 | Mar 3, 2026 | |
| LON: OXB Oxford Biomedica plc | Reiterated: Hold | 550p | 523p | +5.16% | 1 | Dec 8, 2025 | |
| SWX: LONN Lonza Group AG | Reiterated: Buy | CHF 675.00 | CHF 627.80 | n/a | 1 | Jul 28, 2025 |
GSK plc
Oct 21, 2026
Reiterated: Sell
Price Target: 1,700p
Current: 1,871p
Upside: -9.14%
Bachem Holding AG
Sep 10, 2026
Reiterated: Buy
Price Target: CHF 85.00 → CHF 90.00
Current: CHF 84.15
Upside: +6.95%
Euroapi S.A.
May 13, 2026
Reiterated: Hold
Price Target: €1.70
Current: €0.76
Upside: +124.27%
Hikma Pharmaceuticals PLC
Mar 3, 2026
Reiterated: Buy
Price Target: 2,400p → 2,000p
Current: 1,667p
Upside: +19.98%
Oxford Biomedica plc
Dec 8, 2025
Reiterated: Hold
Price Target: 550p
Current: 523p
Upside: +5.16%
Lonza Group AG
Jul 28, 2025
Reiterated: Buy
Price Target: CHF 675.00
Current: CHF 627.80
Upside: n/a